Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Post by hydrocarbsson Jun 09, 2019 9:15pm

205 Views

Post# 29810493

There are a number of PDT trials on record

12 Trials in the EU clinical trails center with both PDT and laser.

https://www.clinicaltrialsregister.eu/ctr-search/search?query=photodynamic+therapy+laser

131 Trials with just PDT in the query.

https://www.clinicaltrialsregister.eu/ctr-search/search?query=photodynamic+therapy

This from Japan in 2015

https://www.kyoto-u.ac.jp/en/research/events_news/department/hospital/news/2015/150526_1.html

PDT is a topical, non-surgical cancer treatment procedure that uses a photosensitizer and a laser to destroy target cells with little impact on the patient's normal tissues and overall health.

While esophageal cancer is treatable and potentially curable with CRT and RT, no standard treatment exists as yet for cases where the tumor has persisted or recurred. In the clinical trial conducted by Professor Muto and others, a staggering 88.5% of patients with persistent or recurred esophageal cancer showed a complete response to PDT.

Bullboard Posts

Microcap Star Diamond releases robust diamond valuation